Article
FADS1/2-mediated lipid metabolic reprogramming drives ferroptosis sensitivity in…
medRxiv · 2023 · Lorito, N.; Subbiani, A.; Smiriglia, A.; Bacci, M.; Bonechi, F.; Tronci, L.; Corrado, A.; Longo, D. L.; Iozzo, M.; Ippolito, L.; Comito, G.; Giannoni, E.; Meattini, I.; Avgustinova, A.; Chiarugi, P.; Bachi, A.; Morandi, A.
Key facts
| Title | FADS1/2-mediated lipid metabolic reprogramming drives ferroptosis sensitivity in triple-negative breast cancer |
|---|---|
| First author | Lorito, N.; Subbiani, A.; Smiriglia, A.; Bacci, M.; Bonechi, F.; Tronci, L.; Corrado, A.; Longo, D. L.; Iozzo, M.; Ippolito, L.; Comito, G.; Giannoni, E.; Meattini, I.; Avgustinova, A.; Chiarugi, P.; Bachi, A.; Morandi, A. |
| Journal | medRxiv |
| Published | Jul 3, 2023 |
| DOI | 10.1101/2023.06.30.547227 |
| Devices mentioned | 204990, 208964, K132071 |
| Product codes mentioned | JJH, JJQ, JQW, LXG, MQV |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1